AstraZeneca Unit and WuXi in China Join to Form Joint Venture

AstraZeneca’s MedImmune unit is joining with a Chinese pharmaceutical outsourcing company to develop an experimental treatment for autoimmune and inflammatory diseases, deepening the British drug developer’s presence in the world’s second-largest economy.
Businessweek